Form 4: Danimer Scientific COO Granted Stock Appreciation Rights and Performance Stock Award

Michael Eric Smith, COO of Danimer Scientific, received stock appreciation rights and a performance stock award on April 3, 2024, under the company's 2020 Long-Term Incentive Plan.

Summary

• On April 3, 2024, Michael Eric Smith, the Chief Operating Officer of Danimer Scientific, Inc., was granted stock appreciation rights (SARs) and a performance stock award (PSA) under the company's 2020 Long-Term Incentive Plan.
• The SARs are for 263,410 shares of the Issuer's Class A common stock, with vesting occurring in three tranches: April 3, 2025 (87,803 shares), April 3, 2026 (87,803 shares), and April 3, 2027 (87,804 shares).
• The PSA consists of 151,585 performance shares of common stock, vesting based on the achievement of Total PHA Revenue and Adjusted EBITDA metrics by December 31, 2026.
• 50% of the performance shares will vest based on Total PHA Revenue, with 50% vesting at $135 million and 100% vesting at $157 million, with pro-rata vesting in between.
• The other 50% of the performance shares will vest based on Adjusted EBITDA, with 50% vesting at $17.2 million and 100% vesting at $22.3 million, with pro-rata vesting in between.
• Vesting of the PSA will occur no later than April 3, 2027, or the Reporting Person's Termination Date, as defined in the Plan.

Sentiment

Score: 7

Explanation: The document is neutral to slightly positive. It outlines standard executive compensation practices, incentivizing the COO to achieve specific financial targets. The performance-based vesting adds a layer of risk, but also potential reward.

Positives

• The granting of SARs and PSAs aligns the COO's interests with the company's performance goals.
• The vesting criteria for the PSA are tied to specific revenue and profitability targets, incentivizing growth and efficiency.
• The long-term vesting schedule encourages the COO's continued commitment to the company.

Risks

• The performance-based vesting of the PSA means that the COO may not receive the full award if the company fails to meet the specified financial targets.
• The value of the SARs is dependent on the future stock price of Danimer Scientific, which is subject to market fluctuations.

Future Outlook

The vesting of the performance stock award is contingent on achieving specific Total PHA Revenue and Adjusted EBITDA targets by the end of fiscal year 2026, indicating the company's focus on growth and profitability.

Industry Context

Executive compensation packages often include stock-based awards to align management's interests with shareholder value. Performance-based awards are common in high-growth companies to incentivize the achievement of ambitious financial targets.

Comparison to Industry Standards

• Comparing Danimer Scientific's executive compensation structure to similar companies in the bioplastics or sustainable materials industry would provide a benchmark for assessing the competitiveness and appropriateness of the awards.
• Companies like Novamont, Corbion, or Avantium could be considered for comparison, focusing on the proportion of stock-based compensation and the specific performance metrics used.
• Analyzing the vesting schedules and target achievement rates of these companies would offer insights into the difficulty and realism of Danimer Scientific's targets.

Stakeholder Impact

• Shareholders: The stock-based compensation aligns management's interests with shareholder value creation.
• Employees: The performance targets may influence company-wide goals and priorities.
• Customers: Achieving revenue targets could lead to increased product availability and innovation.

Key Dates

Keywords

stock appreciation rights, performance stock award, Danimer Scientific, executive compensation, PHA Revenue, Adjusted EBITDA, vesting, DNMR, COO